君实生物(01877.HK)JS212治疗晚期实体瘤的临床试验申请获美国FDA批准

Core Viewpoint - The company Junshi Biosciences (01877.HK) has received approval from the U.S. Food and Drug Administration (FDA) for its clinical trial application of the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors [1] Group 1 - The FDA notification indicates a significant milestone for the company in advancing its oncology pipeline [1] - The approval allows the company to proceed with clinical trials, which could lead to potential market opportunities if successful [1]